The gray market for semaglutide has grown a lot, with poison control centers reporting nearly 3,000 semaglutide-related calls from January through November 2023
In this context, several sensors and pathways regulating the transcription factors, such as activator protein 1 (AP-1), cAMP response element-binding protein (CREB), hypoxia inducible factor-1 (HIF-1), nuclear factor B (NF-B), activating transcription factor 4 (ATF-4), and nuclear factor-erythroid 2-related factor-2 (Nrf2), have been described (Marinho et al

The most commonly reported adverse effects in the Phase 2 clinical trial include: Nausea and vomiting particularly during dose escalation Diarrhoea and constipation Decreased appetite (which contributes to weight loss but may also raise nutritional concerns) Injection site reactions Increases in resting heart rate a signal consistent with other medicines in this class In addition, based on the known class effects of GLP-1-based and incretin therapies (as documented in the Summary of Product Characteristics for licensed comparators such as semaglutide 2.4 mg [Wegovy] and tirzepatide [Mounjaro]), the following risks are relevant to consider in the context of retatrutide's development: Gallbladder disease (including gallstones and cholecystitis) a recognised risk with rapid weight loss and GLP-1 receptor agonism [14] [15] Pancreatitis a potential signal requiring monitoring
Available online at: 127
This could be a documented clinical difference (such as the need for glycine for muscle preservation or a specific dose not available in brand-name pens) or documented inability to obtain the brand-name product
Passengers should never pack tirzepatide in checked luggage due to temperature control concerns and the risk of loss or damage to essential medication